Featured Articles

Developing a Topical Adjunct to Injectable Procedures

By June 24, 2020July 1st, 2020No Comments

Dermatology News

Featured Article

“In vivo testing of bruising resolution demonstrated that at day 2/3, participants using the study product (INhance Post-Injection Serum with TriHex Technology®, Alastin Skincare, Inc. Carlsbad, CA) had 73% less bruise color intensity and statistically significant improvement over the bland moisturizer. “

Read Article Now

Developing a Topical Adjunct to Injectable Procedures

New JDD study reveals 81% of subjects applying a topical product had less bruising at day 2/3 compared to the bland moisturizer.

Injectable procedures have come to play an enormous part in everyday  aesthetic medical practice. Whether its use is directed at volumizing with fillers, decreasing volume using enzymes, skin-tightening using multi-needle approaches, or neuromuscular blockade, the injectable route is the means of delivery in all these cases, making injectable procedures the most common aesthetic procedure performed.

As with all procedures, expected and unexpected consequences may follow including bruising, swelling, discomfort, and the possibility of infection. This paper outlines the scientific process and validation of a product designed as an adjunct to injection therapy and the scientific deep dive needed to encompass both symptomatic and adjunctive purposes. On the symptomatic side, bruising, swelling, and pain were considered, while volumetric enhancement, regeneration, and anti-microbial/biofilm effects were desired outcomes from the adjunctive perspective.

Utilizing peptides and active agents aimed at reducing excess residual iron and stimulating macrophage absorption of red blood cells, we were able to achieve efficient resolution of bruising. In addition, peptides were included to stimulate collagen, elastin, and hyaluronic acid in synergy with the injectable. Anti-inflammatory, antimicrobial, and antibiofilm agents were added to aid in the safety profile of the injectable.

In vivo testing of bruising resolution demonstrated that at day 2/3, participants using the study product (INhance Post-Injection Serum with TriHex Technology®, Alastin Skincare, Inc. Carlsbad, CA) had 73% less bruise color intensity and statistically significant improvement over the bland moisturizer. Overall, 81% of subjects applying the study topical product had less bruising at day 2/3 compared to the bland moisturizer.

Read Article Now
JDD Article Referenced in this Post

You May Also Like

Journal of Drugs in Dermatology JDD Article About Antioxidant, Keratolytic, and Hydrating Treatment for Seborrheic Keratoses. Image from the Full Spectrum of Dermatology: A Diverse and Inclusive Atlas of a darker skin tone back or torso with a seborrheic keratoses.

Antioxidant, Keratolytic, and Hydrating Treatment for Seborrheic Keratoses

| Featured Articles, JDD Highlights, Latest News, The Latest | No Comments
JDD Spotlight: A Novel Topical Approach for Seborrheic Keratoses? Could a new topical formula change the way we manage seborrheic keratoses? In a pilot study, a unique blend of antioxidants,…

JDD in the News: Micropeptide Addresses Aging, Inflammation

| Acne, Derm Community, Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
A recent Journal of Drugs in Dermatology study about a micropeptide with anti-aging and anti-inflammatory effects made news in Dermatology Times. The study, “Acetyl Dipeptide-31 Amide: A Novel Cosmetic Anti-Inflammatory…
Journal of Drugs in Dermatology JDD Article About Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses. Image from the Full Spectrum of Dermatology: A Diverse and Inclusive Atlas of a darker skin tone elbow with psoriasis.

Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses

| Featured Articles, JDD Highlights, Latest News, Psoriasis, The Latest | No Comments
JDD Spotlight: Guselkumab’s 5-Year Promise in Psoriasis Curious about long-term breakthroughs in psoriasis care? A recent pooled analysis from the Phase 3 VOYAGE studies hints that guselkumab might be a…

Leave a Reply